Please ensure Javascript is enabled for purposes of website accessibility

Why Wall Street Is Worried About Pfizer Despite Its COVID Vaccine Success

By Keith Speights - May 13, 2021 at 4:52AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Analysts aren't thinking about the near term -- they're thinking about 2026 and beyond.

Pfizer (PFE -1.40%) just knocked it out of the park with its first-quarter results. Its revenue soared 42% year over year and adjusted earnings per share skyrocketed 48%. The big drugmaker blew away analysts' estimates and significantly raised full-year revenue and earnings guidance.

You might think that Wall Street would have been enthusiastic about such a strong quarterly update. Nope. Pfizer's shares barely moved after the Q1 results were announced. Mizuho Securities analyst Vamil Divan even downgraded Pfizer stock from buy to neutral. 

Wall Street certainly appears to be worried about Pfizer despite its huge COVID-19 vaccine success. But why?

Man with hands on the top of his head and a worried expression looking at a laptop screen with the words Wall Street on a side of a building in the background.

Image source: Getty Images.

Looking to the future

There are two reasons behind some Wall Street analysts' cautious view of Pfizer. Both are connected to the uncertainty about Pfizer's future prospects.

The more near-term concern is that demand for COVID-19 vaccines might fall off dramatically once the pandemic is over. Analysts are reluctant to build models that assume Pfizer's tremendous revenue from its vaccine will continue beyond the next year or so.

It's also important to remember that Pfizer doesn't get to keep all of the sales that it records for the COVID-19 vaccine. The company splits gross profits equally with its partner, BioNTech

However, there's also a potential issue looking even further into Pfizer's future. Mizuho's Divan summed it up in his note to investors: "Cash flows from COVID-19 vaccine sales provide Pfizer with greater optionality, but we wait to see how Pfizer allocates that capital before assessing whether they have improved their 2026-2030 outlook."

Pfizer expects to deliver solid revenue and earnings growth through 2025, even without COVID-19 revenue included. However, the company doesn't talk much about how it might fare after then. The table below might explain why.

Drug

U.S. Basic Patent Expiration

Inlyta 2025
Xeljanz 2025
Prevnar 13 2026
Eliquis 2026
Ibrance 2027
Vyndaqel

2024 (or 2028 with a pending Patent Term Extension)

Xtandi 2027

Source: Pfizer 10-K filing.

In Pfizer's first quarter, several of the drugs listed above ranked among its biggest growth drivers (aside from its COVID-19 vaccine). With a patent cliff on the way, some on Wall Street are understandably nervous.

A different perspective

It might seem like all of Wall Street is skeptical about Pfizer based on the relatively muted performance of the big pharma stock. However, that's not really the case. Of the 22 analysts surveyed by Refinitiv, 12 of them rate the stock as either a buy or a strong buy. That's an increase from only seven analysts with such bullish views in April.

While there have been some concerns about the resilience of Pfizer's COVID-19 revenue, those concerns appear to be decreasing. Pfizer and BioNTech recently signed a deal with the European Union (EU) to supply 900 million doses of their COVID-19 vaccine through 2023, with an option to the EU to purchase another 900 million doses. Pfizer said in its Q1 update that it's in discussions with multiple countries about supply deals for beyond 2021.

The emergence of coronavirus variants seems likely to fuel vaccine demand well into the future. Pfizer CEO Albert Bourla stated in the company's Q1 conference call that the company believes "regular vaccinations" will be required beyond 2022 and 2023.

But what about that patent cliff? First, the expiration of a basic product patent doesn't always mean that exclusivity is immediately lost. Look for Pfizer to do everything it possibly can to retain market share for all of its drugs, including seeking to enforce other patents to retain exclusivity.

Don't forget Pfizer's pipeline. The company currently has 100 programs in clinical development, with 32 in late-stage testing or awaiting regulatory approval. It also trounces the industry averages in clinical-trial success rates.

Pfizer's COVID-19 vaccine will generate a lot of extra cash for the company, as well. One of the top ways that drugmakers have navigated through the loss of patent exclusivity in the past is through acquisitions. Pfizer should see its financial flexibility to make smart strategic deals improve over the next couple of years.

The Jerry McGuire solution

What will it take for Pfizer to convince analysts that its future really is a bright one? I suspect the solution is, in the words of Cuba Gooding Jr.'s character in Jerry McGuire, "Show me the money."

Pfizer projects that its COVID-19 vaccine will generate sales of $26 billion this year. If the company comes close to raking in that same amount in 2022 and the prospects of strong recurring revenue look good, my hunch is that Wall Street's worries will diminish considerably. 

Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$48.58 (-1.40%) $0.69
BioNTech SE Stock Quote
BioNTech SE
BNTX
$147.61 (-2.91%) $-4.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.